As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.

Following a merger with DCPrime in December 2020, Immunicum is developing two complementary approaches using allogeneic dendritic cells derived from monocytes from a healthy donor or from a human ...

Dendritic cell-based vaccines are a promising approach to cancer treatment. Many drugs are in clinical trials, and one was ...

Over the past ten years, we have investigated the developmental origin and homeostasis of macrophages and the related cell types monocytes and dendritic cells. These cells play a major role in diverse ...

Two melanoma cell line models derived from mice that respond ... the cancer immunity cycle in the lymph node, both dendritic cells and monocytes are needed to fully activate T cells in the tumor.

Conventional dendritic cells, for example ... of "cross-dressing," a process where monocytes acquire and present tumor antigens. Tumor-derived factors such as prostaglandin E2 (PGE2) and type ...